BiotechTube

abciximab placebo; reteplase placebo, abciximab, abciximab + Abciximab; reteplase; abciximab placebo; abciximab + abciximab; reteplase placebo; abciximab placebo; abciximab + abciximab placebo; reteplase placebo, abciximab, abciximab + abciximab; reteplase placebo; abciximab placebo; abciximab + Abciximab; reteplase; abciximab placebo; abciximab

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Myocardial Infarction

Conditions

Myocardial Infarction

Trial Timeline

Aug 1, 2002 → Jan 1, 2008

NCT ID
NCT00046228

About abciximab placebo; reteplase placebo, abciximab, abciximab + Abciximab; reteplase; abciximab placebo; abciximab + abciximab; reteplase placebo; abciximab placebo; abciximab + abciximab placebo; reteplase placebo, abciximab, abciximab + abciximab; reteplase placebo; abciximab placebo; abciximab + Abciximab; reteplase; abciximab placebo; abciximab

abciximab placebo; reteplase placebo, abciximab, abciximab + Abciximab; reteplase; abciximab placebo; abciximab + abciximab; reteplase placebo; abciximab placebo; abciximab + abciximab placebo; reteplase placebo, abciximab, abciximab + abciximab; reteplase placebo; abciximab placebo; abciximab + Abciximab; reteplase; abciximab placebo; abciximab is a phase 3 stage product being developed by Eli Lilly for Myocardial Infarction. The current trial status is completed. This product is registered under clinical trial identifier NCT00046228. Target conditions include Myocardial Infarction.

What happened to similar drugs?

20 of 20 similar drugs in Myocardial Infarction were approved

Approved (20) Terminated (3) Active (0)
✅AbciximabEli LillyApproved
✅AbciximabEli LillyApproved
✅abciximabEli LillyApproved
✅Ticagrelor + ClopidogrelAstraZenecaApproved
✅ticagrelor + aspirinAstraZenecaApproved
✅Ticagrelor + PlaceboAstraZenecaApproved
✅Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)AstraZenecaApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00046228Phase 3Completed

Competing Products

20 competing products in Myocardial Infarction

See all competitors
ProductCompanyStageHype Score
Butylphthalide + Butylphthalide placeboCSPC Pharmaceutical Group LimitedPhase 3
47
AbciximabEli LillyApproved
43
Prasugrel + ClopidogrelDaiichi SankyoPhase 3
40
Regadenoson + gadofoveset trisodiumAstellas PharmaPhase 2
35
Half-dose of the Tc99-m sestamibi (Cardiolite)Astellas PharmaPre-clinical
18
No interventionAstellas PharmaPre-clinical
22
Empagliflozin + PlaceboEli LillyPhase 3
40
Abciximab + Abciximab placeboEli LillyPhase 3
36
Intracoronary infusion of enriched bone marrow-derived progenitor cells + Placebo medium supplemented with autologous serumEli LillyPhase 3
40
AbciximabEli LillyApproved
43
fibrinolytic therapy or combination reduced fibrinolytic therapyEli LillyPhase 3
40
abciximabEli LillyApproved
43
tenecteplase + enoxaparin + clopidogrelEli LillyPhase 2/3
38
Thrombolytic therapyEli LillyPre-clinical
22
TicagrelorAstraZenecaPre-clinical
26
TicagrelorAstraZenecaPhase 2
31
Dual-antiplatelet therapy + Dual-antiplatelet therapyAstraZenecaPre-clinical
22
Metoprolol- Toprol XL + Metoprolol- LopressorAstraZenecaPhase 1
29
Ticagrelor orodispersible tablets + Ticagrelor standard tabletsAstraZenecaPhase 3
40
RosuvastatinAstraZenecaPhase 3
40